Lobe Sciences Ltd. logo

Lobe Sciences Ltd. (LOBE)

Market Closed
3 Jun, 20:00
CNSX CNSX
CA$
0. 1000
+0.01
+11.11%
CA$
38.35M Market Cap
- P/E Ratio
- Div Yield
26,300 Volume
0 Eps
CA$ 0.09
Previous Close
Add Transaction
Day Range
0.1 0.115
Year Range
0.025 0.18
Want to track LOBE and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

LOBE closed today higher at CA$0.1, an increase of 11.11% from yesterday's close, completing a monthly decrease of -23.08% or -CA$0.03. Over the past 12 months, LOBE stock gained 122.22%.
LOBE is not paying dividends to its shareholders.
The last earnings report, released on Apr 27, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Lobe Sciences Ltd. has completed 2 stock splits, with the recent split occurring on Jun 10, 2022.
The company's stock is traded on 3 different exchanges and in various currencies, with the primary listing on CNSX (CAD).

LOBE Chart

People also search for

C21 Investments Inc.
CA$ 0.37
-1.33%
Bionxt Solutions Inc.
CA$ 0.38
-7.32%
SCU
Sankamap Metals Inc.
CA$ 0.39
+2.63%
VOY
Evolve Royalties Ltd.
CA$ 0.84
-1.18%
CanaFarma Hemp Products Corp.
CA$ 0.05
0%

Lobe Sciences Ltd. (LOBE) FAQ

What is the stock price today?

The current price is CA$0.1000.

On which exchange is it traded?

Lobe Sciences Ltd. is listed on CNSX.

What is its stock symbol?

The ticker symbol is LOBE.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 38.35M.

Has Lobe Sciences Ltd. ever had a stock split?

Lobe Sciences Ltd. had 2 splits and the recent split was on Jun 10, 2022.

Lobe Sciences Ltd. Profile

Specialty Retail Industry
Consumer Discretionary Sector
Frederick Dominick Sancilio CEO
CNSX Exchange
CA53946V2066 ISIN
CA Country
- Employees
- Last Dividend
10 Jun 2022 Last Split
- IPO Date

Overview

Lobe Sciences Ltd. is a pioneering biopharmaceutical entity dedicated to harnessing the potential of proprietary psychedelic substances with the aim of advancing brain health, mental wellness, and overall cognitive function. The company operates at the forefront of a burgeoning field of medicine that seeks to leverage sub-hallucinogenic dosages of psychedelic compounds to address a variety of neurological and psychiatric conditions. Initially known as Greenstar Biosciences Corp., the organization underwent a significant rebranding in November 2020, emerging as Lobe Sciences Ltd., to better reflect its focused mission and expanding research endeavors. With its headquarters firmly established in Vancouver, Canada, Lobe Sciences Ltd. represents a blend of innovative research and steadfast dedication to finding novel solutions within the health and wellness landscape.

Products and Services

  • Research and Development in Psychedelic Compounds

    At the core of Lobe Sciences Ltd.'s operations is its intensive research and development efforts surrounding psychedelic substances. These endeavors are targeted at uncovering and harnessing the therapeutic potential of sub-hallucinatory doses of these compounds. The ultimate goal is to develop treatments that can significantly improve mental health outcomes, enhance cognitive abilities, and foster an overall state of wellness in individuals facing neurological and psychiatric challenges.

Contact Information

Address: 1199 West Hastings Street
Phone: 949-505-5623